Recent developments include quarterly earnings transcripts for Q1 and Q2 2026, initiation of coverage by Jones Trading with a buy recommendation, FDA clearance for the OneRF Trigeminal Nerve Ablation System, significant revenue growth in Q3 2025, and key patent allowances and clinical milestones.

• NeuroOne released its Q2 2026 earnings transcript detailing operational and financial results [N1].
• Jones Trading initiated coverage of NeuroOne Medical Technologies with a buy recommendation in March 2026 [N2].
• The company held its Q1 2026 earnings call and published the transcript in February 2026 [N3].
• NeuroOne received FDA clearance for the OneRF Trigeminal Nerve Ablation System in August 2025 [N4].
• The company reported a 105% revenue increase in Q3 2025, as detailed in multiple news articles and earnings call transcripts [N5][N6][N7].
• NeuroOne secured a notice of allowance for a key neural probe patent in July 2025 [N8].
• The company reported a successful seizure-free milestone in the first patient treated with the OneRF Ablation System in June 2025 [N8].
• Recent executive appointments include Emily Johns as General Counsel and Corporate Secretary and Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor to enhance clinical development strategy [N8].

NeuroOne has achieved FDA clearance for multiple products and demonstrated significant revenue growth, including a 105% increase in Q3 2025. The company has secured key intellectual property rights and established an exclusive global distribution partnership with Zimmer, which could facilitate market penetration. Recent clinical milestones, such as a successful seizure-free outcome in a patient treated with the OneRF Ablation System, support the clinical potential of its technologies. The addition of experienced executives and advisors may enhance clinical development and commercialization efforts. These factors contribute to the company's potential to expand its presence in the neuromodulation market.

The company has incurred substantial operating losses since inception and has an accumulated deficit of $84.4 million as of June 30, 2026, with ongoing net losses and limited cash resources raising substantial doubt about its ability to continue as a going concern. NeuroOne is highly dependent on Zimmer for commercialization, and any failure by Zimmer to meet purchase requirements or effectively market products could materially harm the business. Supply chain disruptions and delays in component availability have caused backorders and could continue to impact operations. The company faces intense competition from larger, well-capitalized medical device companies with established market presence. Material weaknesses in internal controls and the need for additional capital raise operational and financial risks. These factors present significant challenges to the company's sustainability and growth.

NeuroOne's moat is primarily based on its proprietary neuromodulation technologies and FDA-cleared products, including the OneRF Ablation System and related devices. The company has secured intellectual property protections, such as a notice of allowance for a key neural probe patent. Its exclusive global distribution agreement with Zimmer provides a commercial channel for its products. However, the company faces significant competition from well-established medical device companies with greater resources, broader product portfolios, and more extensive sales and marketing capabilities. The company's limited operating history, reliance on third-party suppliers, and dependence on a single distributor constrain its competitive position. The moat is thus moderate, supported by technology and regulatory clearances but challenged by market and operational risks.

• Going Concern and Profitability Risk: The company has incurred significant losses since inception, with an accumulated deficit of $84.4 million as of June 30, 2026, and management has raised substantial doubt about its ability to continue as a going concern.
• Dependence on Zimmer Distribution Agreement: NeuroOne relies exclusively on Zimmer for global distribution of key products until 2034. Failure by Zimmer to meet obligations, achieve sales milestones, or manage inventory effectively could materially impact NeuroOne's sales and financial results.
• Supply Chain and Manufacturing Risks: The company depends on a limited number of third-party suppliers and manufacturers. Delays, quality issues, or regulatory non-compliance by suppliers could disrupt production, cause backorders, and negatively affect sales and reputation.
• Competition: NeuroOne faces competition from well-established medical device companies with greater resources, broader product portfolios, and more extensive sales and marketing capabilities, which may limit market adoption of NeuroOne's products.
• Internal Control Deficiencies: Material weaknesses in internal controls over financial reporting, including revenue recognition, have led to restatements and could result in further misstatements, regulatory scrutiny, or loss of investor confidence.
• Capital Requirements and Dilution: The company requires additional capital to fund operations and development. Failure to raise capital on acceptable terms could force operational curtailments or dilution of existing shareholders.
• Regulatory and Reimbursement Risks: Obtaining and maintaining regulatory clearances and adequate reimbursement is critical. Delays or failures in these areas could adversely affect commercialization and revenue generation.

• NeuroOne Medical Technologies Corp is an early-stage medical technology company focused on developing and commercializing neuromodulation sEEG monitoring, ablation, and stimulation solutions for neurological disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, facial pain, and chronic back pain [S2].
• The company has four FDA 510(k) cleared products: Evo Cortical, Evo sEEG Electrode, OneRF Ablation System, and OneRF TN Ablation System [S2].
• NeuroOne has an exclusive global distribution agreement with Zimmer for the Evo Cortical, Evo sEEG, and OneRF Ablation System in the brain until 2034, making the company reliant on Zimmer for commercialization and sales [S2].
• The company has experienced significant operating losses since inception, with an accumulated deficit of $84.4 million as of June 30, 2026, and has never been profitable [S2].
• As of June 30, 2026, NeuroOne had cash and cash equivalents of approximately $2.05 million and current assets of about $5.79 million, with current liabilities of approximately $2.04 million, resulting in a current ratio of 2.84 and a cash ratio of 1.49 [S2].
• For the quarter ended June 30, 2026, the company reported revenue of approximately $1.97 million and a net loss of about $2.01 million, with basic and diluted EPS of -$0.23 and -$0.28 respectively [S2].
• The company has limited operating history and limited sales of commercialized products, with operations primarily financed through public and private offerings of common stock and convertible debt [S2].
• NeuroOne depends on a limited number of third-party suppliers and manufacturers for components and products, exposing it to risks related to supply delays, quality, and regulatory compliance [S2].
• The company has experienced delays in component and raw material availability, resulting in backorders and delayed customer order fulfillment [S2].
• Management has raised substantial doubt about the company's ability to continue as a going concern due to ongoing losses and limited capital resources [S2].
• The company has identified material weaknesses in internal controls over financial reporting, including revenue recognition, which led to restatement of financial statements for the quarter ended March 31, 2026 [S2].
• NeuroOne's business and operating results are subject to risks related to Zimmer's inventory management decisions, including potential postponement of product purchases that could negatively impact sales and working capital [S2].
• The company faces competition from well-established and well-capitalized competitors with greater resources, experience, and market presence [S2].
• Recent news includes Q2 2026 earnings call transcript and coverage initiation by Jones Trading with a buy recommendation [N1][N2].
• The company received FDA clearance for the OneRF Trigeminal Nerve Ablation System in August 2025 [N4].
• NeuroOne reported a 105% revenue increase in Q3 2025 [N5][N7].
• The company secured a notice of allowance for a key neural probe patent in July 2025 [N8].
• NeuroOne reported a successful seizure-free milestone in the first patient treated with the OneRF Ablation System in June 2025 [N8].
• Recent executive appointments include Emily Johns as General Counsel and Corporate Secretary in June 2025 and Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor in May 2025 [N8].